Gestational Diabetes Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Gestational Diabetes Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)
Gestational Diabetes Market is segmented By Treatment (Insulin Therapy, Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin, Oral Medications, Metformin, Sulfonylureas), By Diagnosis (Glucose Challenge Test, Oral Glucose Tolerance Test), By End User (Hospitals, Clinics, Home Care Settings, Diagnostic Centers), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD Billion) for the above-mentioned segments.
Gestational Diabetes Market is segmented By Treatment (Insulin Therapy, Rapid-Acting Insulin, Short-...
Gestational Diabetes Market Size - Analysis
The gestational diabetes market is estimated to be valued at USD 9.4 Bn in 2024 and is expected to reach USD 17.1 Bn by 2031, growing at a compound annual growth rate (CAGR) of 8.9% from 2024 to 2031. An increasing number of risk factors associated with gestational diabetes such as rising obesity levels, older maternal age during pregnancy and sedentary lifestyles are contributing to the rising disease incidence. However, the lack of symptoms in early stages of gestational diabetes remains a major challenge.
Market Size in USD Bn
CAGR8.9%
Study Period
2024 - 2031
Base Year of Estimation
2023
CAGR
8.9%
Market Concentration
Medium
Major Players
Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Merck & Co., Inc., F. Hoffmann-La Roche Ltd and Among Others
*Disclaimer: Major players are listed in no particular order.
*Source: Coherent Market Insights
Want to purchase customized report? please let us know !
Gestational Diabetes Market Trends
Market Driver - Rising Obesity Rates and Advanced Maternal Age
As more women are waiting until later in life to have children, advanced maternal age has also been linked to a higher risk of gestational diabetes. As women age, their bodies' ability to produce and respond to insulin can decline over time. When pregnancy hormones alter everything from metabolism to blood circulation, an older woman may face greater challenges keeping her blood sugar stable.
Some research has indicated the risk increases somewhat linearly after age 25. With so many health organizations now recognizing obesity as a global epidemic, and birthrates for women in their 30s and 40s on the rise in many Western nations, this combination of factors has served to drive up the number of gestational diabetes cases seen each year.
More overweight or obese women of advancing maternal age means a growing population at higher risk entering pregnancy. Until nations are more successful at stemming obesity rates across all demographics, and social norms around family planning change again, these trends will continue contributing significantly to the increased disease burden of gestational diabetes.
Market Driver - Development of Advanced Diagnostic Tools and Insulin Delivery Systems
As medical science advances our understanding of diabetes and develops new technologies, providers have gained improved ability to both screen for and safely manage cases of gestational diabetes. Standardized oral glucose tolerance tests can more uniformly identify at-risk patients. Continuous glucose monitors also give clinicians highly granular readouts of an expectant mother's constant fluctuations in blood sugar levels over days or weeks.
These enhanced detection capacities have naturally resulted in higher reported instance of the disease as more mild or short-lived cases are picked up. Insulin pumps, pens, and other user-friendly delivery mechanisms as well have emboldened doctors' willingness and ability to actively treat the condition when necessary.
The improved medical surveillance and management options provided by new diagnostic devices and therapeutic regimens not only benefit patient outcomes but have elevated recognition of the full prevalence of gestational diabetes within populations. In being better able to identify and accommodate more cases, the advanced care technologies now available have unavoidably contributed to higher reported rates and incidence statistics of this condition.
Market Challenge - The Expense of Insulin Therapies and Monitoring Devices
One of the major challenges facing the gestational diabetes market is the expense of insulin therapies and continuous glucose monitoring devices. Treating gestational diabetes often requires intensive insulin treatment which can be an economic burden for many patients. Not only is insulin itself expensive, patients may need to test their blood glucose levels several times a day. This requires buying test strips and lancets on a regular basis.
For those choosing to use continuous glucose monitors, the upfront costs can be several hundred dollars and many insurance plans do not fully cover these devices. The out-of-pocket costs of managing this condition throughout pregnancy can rapidly add up and act as a barrier to effective treatment. This represents a challenge for healthcare providers and device manufacturers aiming to improve diagnosis and treatment rates.
High treatment expenses may also impact adherence if patients cannot consistently afford the supplies needed. Addressing the costs associated with insulin and monitoring technologies is important to expand access and help more women receive the care they need.
Market Opportunity - Untapped Markets in Asia-Pacific and Africa Present Significant Growth Potential
One of the major opportunities in the gestational diabetes market is the potential for growth in under-screened and underserved regions such as Asia-Pacific and Africa. Rates of gestational diabetes are increasing globally due to rising obesity levels and older maternal ages.
However, screening and diagnosis rates remain relatively low in many developing nations where risk factors are prevalent. This represents an untapped market for device manufacturers and service providers. As awareness increases and screening protocols improve in these regions, the number of cases identified is projected to rise significantly in the coming years.
With a combined population of over 4 billion people, Asia-Pacific and Africa have the capacity to drive huge gains in the gestational diabetes market. By introducing more affordable solutions and innovative care models, companies operating in these regions have an opportunity to reach massive numbers of undiagnosed women and help establish standards of treatment. This growth potential presents a valuable opportunity for stakeholders to expand their customer bases and drive future revenue growth.
Treatment Option Analysis of Gestational Diabetes Market
Gestational diabetes is typically treated through diet, exercise, glucose monitoring and medication if needed.
In mild cases, lifestyle changes such as a healthy diet and activity are the first-line treatment. This involves balancing carbohydrate, fat and protein intake across meals to control blood sugar levels. Regular exercise aids insulin sensitivity. Self-monitoring blood glucose using a glucometer helps determine individual response to foods.
If lifestyle interventions are insufficient, oral hypoglycemic drugs are prescribed. Metformin is most commonly used as the initial medication due to its favorable safety profile during pregnancy. It works by improving how the body uses insulin and regulating liver glucose production. For patients who cannot maintain control on metformin alone, insulin therapy is initiated. Both intermediate- and long-acting insulin analogs such as Glargine and Detemir are preferred over regular human insulin to reduce risks of low blood sugar events.
Close monitoring by an obstetrician and diabetes specialist is vital throughout treatment to prevent complications arising from uncontrolled hyperglycemia like premature delivery and macrosomia. A multidisciplinary approach focusing on medical nutrition therapy, glucose monitoring, exercise and pharmacotherapy tailored to the stage of disease helps optimize outcomes for both mother and baby.
Key winning strategies adopted by key players of Gestational Diabetes Market
Research and development of novel treatments: One of the major strategies adopted by leading players like Sanofi, Merck, and Eli Lilly has been extensive research and development of novel drugs and treatment options for gestational diabetes. For example, Sanofi invested over $500 million in 2015 to develop insulin Aspart, a fast-acting insulin analog, for managing blood sugar levels in pregnant women with gestational diabetes.
Partnerships and collaborations: Companies have recognized that teaming up with other players enables broader patient reach and development of advanced solutions. Novo Nordisk partnered with Abbott in 2020 to integrate their continuous glucose monitoring (CGM) devices with Novo Nordisk's diabetes management apps.
Awareness campaigns: Increased awareness about the risks of uncontrolled gestational diabetes and the importance of optimal treatment can drive early screening and diagnosis. In 2018, Medtronic conducted large-scale awareness initiatives in the US and Europe through digital campaigns, social media engagement and physician education programs. This helped in early identification of over 10,000 new cases.
Acquisitions: Companies acquire smaller innovative firms to gain access to novel technology platforms and products in gestational diabetes management. In 2021, Roche acquired mySugr to bolster its digital health portfolio with mySugr's app and CGM integration capabilities.
Segmental Analysis of Gestational Diabetes Market
Insights, By Treatment: Effective Management of Blood Sugar Levels Drives Growth of Insulin Therapy
Insulin therapy is estimated to account for 55.3% revenue share of the gestational diabetes market in 2024, due to its proven effectiveness in managing blood sugar levels. Insulin Therapy works directly to lower blood glucose and thus helps lower the risks associated with high blood sugar during pregnancy such as premature birth, large birth weight, birth injuries, and high blood sugar in the baby after birth.
Within Insulin Therapy, long-acting insulin varieties like glargine and detemir have gained considerable popularity as they offer steady and prolonged glycemic control throughout the day with just one daily dose. This convenience of long-acting insulin therapy improves compliance for pregnant women. Short-acting and rapid-acting insulin varieties are also widely used depending on mealtimes to effectively manage post-prandial glucose peaks. Insulin is highly effective even for women with more severe diabetes who may require higher doses. Its efficacy and ability to be customized through dosing regimens make it the preferred treatment method for optimizing blood sugar control during pregnancy.
Women are also more comfortable with insulin therapy as they perceive it as a more proactive approach to managing their condition during this crucial stage. The efficacy, safety, and customizability of insulin therapy thus drive its large share of the gestational diabetes treatment market.
Insights, By Diagnosis: Non-invasive Nature Drives Adoption of Glucose Challenge Test
The Glucose Challenge Test (GCT) is projected to account for 60.7% share of the gestational diabetes market owing to its non-invasive nature. The GCT involves drinking a sugary beverage and then checking blood glucose levels one hour later through a simple blood test.
This single blood draw methodology makes it more acceptable to pregnant women compared to the multi-blood draw Oral Glucose Tolerance Test (OGTT) procedure. The convenience and minimal invasiveness of the GCT helps address issues like needle phobia and reluctance to undergo multiple finger pricks that are required for OGTT.
GCT screening is also routinely recommended between 24-28 weeks of pregnancy as part of standard antenatal care in many countries. Its inclusion in regular check-ups and simplicity have resulted in high screening rates. At the same time, studies show the GCT to have reasonable accuracy at detecting gestational diabetes risk when used appropriately. For low-risk women, a negative GCT screening offers reassurance without the need for a more involved OGTT. Even obstetricians prefer the GCT as a preliminary screening approach due to its non-invasive properties.
Overall, pregnant women find the single blood draw methodology less bothersome and disruptive to their daily routine compared to multi-step OGTT. This improved acceptability and convenience drives higher adoption of GCT as the preferred initial screening method for gestational diabetes.
Insights, By End User: Advanced Facilities and Expertise Drive Preference for Hospitals
Hospitals account for the largest share of the gestational diabetes market due to advantages in terms of advanced facilities and clinical expertise. Women diagnosed with gestational diabetes often have complex care needs involving multidisciplinary teams of specialists like endocrinologists, diabetologists, dietitians, and obstetricians. Hospitals are best equipped to provide this comprehensive care due to presence of multiple departments and practitioners under one roof. They also have facilities like advanced glucose monitors, insulin pumps, and round-the-clock monitoring in case of emergencies or fluctuations in blood sugar.
Gestational diabetes also carries higher risks for both mother and baby compared to normal pregnancies. Hospitals have 24/7 intensive care and neonatal intensive care units required to handle any pregnancy or delivery complications. Particularly for women with more severe forms of diabetes, specialist care and monitoring available only at hospitals provides greater peace of mind. Hospitals also conduct advanced prenatal screening and diagnostics like oral glucose tolerance tests. Women therefore prefer the superior infrastructure and multidisciplinary approach offered by hospitals during this high-risk stage of pregnancy.
On the whole, hospitals are best equipped to balance the health goals of controlling diabetes and ensuring a healthy pregnancy outcome, thereby attracting the largest share of gestational diabetics.
Additional Insights of Gestational Diabetes Market
Prevalence Rate: GDM affects approximately 7-14% of pregnancies worldwide.
Complications: Women with GDM have a higher risk of developing type 2 diabetes later in life.
The increasing collaboration between pharmaceutical companies and healthcare providers to improve patient education on GDM management.
Government initiatives in countries like China and India to screen all pregnant women for gestational diabetes.
Competitive overview of Gestational Diabetes Market
The major players operating in the gestational diabetes market include Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Medtronic plc, Abbott Laboratories, AstraZeneca plc, Boehringer Ingelheim GmbH, and Johnson & Johnson.
Gestational Diabetes Market Leaders
Novo Nordisk A/S
Eli Lilly and Company
Sanofi S.A.
Merck & Co., Inc.
F. Hoffmann-La Roche Ltd
*Disclaimer: Major players are listed in no particular order.
Gestational Diabetes Market - Competitive Rivalry
Gestational Diabetes Market
Market Consolidated (Dominated by major players)
Market Fragmented (Highly competitive with lots of players.)
*Source: Coherent Market Insights
Recent Developments in Gestational Diabetes Market
In July 2023, Novo Nordisk launched a new fast-acting insulin formulation aimed at improving postprandial glucose control in pregnant women with GDM. Novo Nordisk has been heavily involved in developing various fast-acting insulins, such as Fiasp (a faster-acting version of insulin aspart), which has been studied for improving post-meal blood sugar control across different populations, including individuals with type 1 and type 2 diabetes.
In May 2023, Abbott Laboratories received FDA approval for their continuous glucose monitoring system specifically designed for pregnant women. Abbott's FreeStyle Libre 2 and FreeStyle Libre 3 CGM systems were cleared by the FDA for use in women with diabetes during pregnancy, including those with gestational diabetes. These systems are also approved for use by children as young as two years old, offering real-time glucose monitoring with extended wear times.
In March 2023, Eli Lilly and Company announced a partnership with local clinics in India to provide affordable insulin therapies. Eli Lilly has been actively involved in efforts to make insulin more affordable globally. The company announced a 70% price reduction for its most commonly prescribed insulin products and expanded its Insulin Value Program, which caps patient out-of-pocket costs at $35 per month in the U.S.
Gestational Diabetes Market Report - Table of Contents
RESEARCH OBJECTIVES AND ASSUMPTIONS
Research Objectives
Assumptions
Abbreviations
MARKET PURVIEW
Report Description
Market Definition and Scope
Executive Summary
Gestational Diabetes Market, By Treatment
Gestational Diabetes Market, By Diagnosis
Gestational Diabetes Market, By End User
Coherent Opportunity Map (COM)
MARKET DYNAMICS, REGULATIONS, AND TRENDS ANALYSIS
Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER’s Analysis
Merger and Acquisition Scenario
Global Gestational Diabetes Market, By Treatment, 2024-2031, (USD Bn)
Introduction
Market Share Analysis, 2024 and 2031 (%)
Y-o-Y Growth Analysis, 2019 - 2031
Segment Trends
Insulin Therapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Rapid-Acting Insulin
Short-Acting Insulin
Intermediate-Acting Insulin
Long-Acting Insulin
Oral Medications
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Metformin
Sulfonylureas
Global Gestational Diabetes Market, By Diagnosis, 2024-2031, (USD Bn)
Introduction
Market Share Analysis, 2024 and 2031 (%)
Y-o-Y Growth Analysis, 2019 - 2031
Segment Trends
Glucose Challenge Test (GCT)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Oral Glucose Tolerance Test (OGTT)
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Global Gestational Diabetes Market, By End User, 2024-2031, (USD Bn)
Introduction
Market Share Analysis, 2024 and 2031 (%)
Y-o-Y Growth Analysis, 2019 - 2031
Segment Trends
Hospitals
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Clinics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Home Care Settings
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Diagnostic Centers
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Global Gestational Diabetes Market, By Region, 2019 - 2031, Value (USD Bn)
Introduction
Market Share (%) Analysis, 2024,2027 & 2031, Value (USD Bn)
Market Size and Forecast, By Treatment, 2019 - 2031, Value (USD Bn)
Market Size and Forecast, By Diagnosis, 2019 - 2031, Value (USD Bn)
Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
U.S.
Canada
Latin America
Introduction
Market Size and Forecast, By Treatment, 2019 - 2031, Value (USD Bn)
Market Size and Forecast, By Diagnosis, 2019 - 2031, Value (USD Bn)
Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
Brazil
Argentina
Mexico
Rest of Latin America
Europe
Introduction
Market Size and Forecast, By Treatment, 2019 - 2031, Value (USD Bn)
Market Size and Forecast, By Diagnosis, 2019 - 2031, Value (USD Bn)
Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, By Treatment, 2019 - 2031, Value (USD Bn)
Market Size and Forecast, By Diagnosis, 2019 - 2031, Value (USD Bn)
Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, By Treatment, 2019 - 2031, Value (USD Bn)
Market Size and Forecast, By Diagnosis, 2019 - 2031, Value (USD Bn)
Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
GCC Countries
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, By Treatment, 2019 - 2031, Value (USD Bn)
Market Size and Forecast, By Diagnosis, 2019 - 2031, Value (USD Bn)
Market Size and Forecast, By End User, 2019 - 2031, Value (USD Bn)
South Africa
North Africa
Central Africa
COMPETITIVE LANDSCAPE
Novo Nordisk A/S
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Eli Lilly and Company
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Sanofi S.A.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Merck & Co., Inc.
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Hoffmann-La Roche Ltd
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Medtronic plc
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Abbott Laboratories
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
AstraZeneca plc
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Boehringer Ingelheim GmbH
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Johnson & Johnson
Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
Analyst Recommendations
Wheel of Fortune
Analyst View
Coherent Opportunity Map
References and Research Methodology
References
Research Methodology
About us
Gestational Diabetes Market Segmentation
By Treatment
Insulin Therapy
Rapid-Acting Insulin
Short-Acting Insulin
Intermediate-Acting Insulin
Long-Acting Insulin
Oral Medications
Metformin
Sulfonylureas
By Diagnosis
Glucose Challenge Test (GCT)
Oral Glucose Tolerance Test (OGTT)
By End User
Hospitals
Clinics
Home Care Settings
Diagnostic Centers
Would you like to explore the option of buyingindividual sections of this report?
About author
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
Frequently Asked Questions :
How big is the gestational diabetes market?
The gestational diabetes market is estimated to be valued at USD 9.4 Bn in 2024 and is expected to reach USD 17.1 Bn by 2031.
What are the key factors hampering the growth of the gestational diabetes market?
The expense of insulin therapies and monitoring devices can be prohibitive. In addition to this, lack of awareness about GDM in developing regions hampers market growth. These are the major factors hampering the growth of the gestational diabetes market.
What are the major factors driving the gestational diabetes market growth?
The rising obesity rates and advanced maternal age contribute to the increasing incidence. In addition to this, development of advanced diagnostic tools and insulin delivery systems is the major factors driving the gestational diabetes market.
Which is the leading treatment in the gestational diabetes market?
The leading treatment segment is insulin therapy.
Which are the major players operating in the gestational diabetes market?
Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Merck & Co., Inc., F. Hoffmann-La Roche Ltd, Medtronic plc, Abbott Laboratories, AstraZeneca plc, Boehringer Ingelheim GmbH, and Johnson & Johnson are the major players.
What will be the CAGR of the gestational diabetes market?
The CAGR of the gestational diabetes market is projected to be 8.9% from 2024-2031.